Clinical ethics is an intrinsic aspect ofmedical practice. Concerns for ethical conduct arise in the management of medical benefits, patient preferences, quality oflife, and the relationship between patient care and its attendan t fa milial, social, economic, and legal circumstances.
Introduction
Ethic s is the study of perfect conduct-what we should do and what is the ju st and moral cour se of actions and beliefs. Like logic and metaph ysics, ethics is one of the disciplines of philo sophical discourse. As physicians, our concern lies not so much with meta-ethic s (the natur e of ethic al theory or j udgment), but rather with norm ative ethics (the application of these concept s) and its impact on the framework of our profession and its relat ionship to the practice of medicine. Thi s discourse on medic al ethics 
ORTH §CNEIL
The following treatment-related adverse events we re each reported in a sing le subject: dermatitis, eczema , erythe mato us rash, follicular rash, rash , hypoaesthesia, tinnitus, dyspe psia, hot flushes, flushing, and otorrhagia.
Subjects wit h Acute Otitis Med ia with Tympanostomy Tubes and Subjects with Chro nic

Suppurative Otitis Media with Perforated Tympanic Membranes
The following treatment-related adverse events occurr ed in 1% or more of the subj ects wit h non-intact tympanic membranes.
of 810 mglkg/day. Of loxacin has not bee n shown to be teratoge nic at doses as high as 810 mg/kg/day and 160 mglkg/day when admi nistered to preg nant rats and rabbits , respectively.
Ofloxacin has not been show n to have any adverse effects on the developi ng embryo or fetus at doses relevant to the amount of ofloxaci n that will be delivere d ototopica lly at the reco mmende d clinical doses.
No nte rat og enic Eff ect s : Additional studies in the rat de monstrated that doses up to 360 mglkg/day dur ing late gestat ion had no adverse effects on late fetal developme nt, labor, delivery, lactation, neonatal viability, or growth of the newborn . There are, however , no adequate and we ll-controlled studies in pregnant women . FLOXIN'" Otic should be used during pregnancy only if the potential benef it justifies the potential risk to the fetus. Nursing Mot hers: In nursi ng women, a sing le 200 rng oral dose resulted in conce ntrations of olloxaci n in milk which we re similar to those found in plasma . It is not known whether ofloxacin is excreted in human milk following topica l otic administration . Because of the potential for serious adverse reactions from ofloxacin in nursing infants, a decision shouldbe made whether to disco ntinue nursing or to disco ntinue the drug, taking into acco unt the impo rtance of the drug to the mother. Pedi at ric Use : No changes in hearing function occu rred in 30 pediatric subjects freated wit h ofloxacin otic and tested for audiometric parameters. Althoug h safety and efficacy have been demo nstrated in ped iatric patients one year and olde r, safety and effectiveness in infants be low the age of one year have not been esta blishe d. Although quinolones, including olloxac in, have been show n to ca use arthropathy in immature animals after systemic admi nistration, young growing guinea pigs dose d in the middle ear with 0.3% otloxacin otic solution for one month showed no syste mic effects, quinolone-induced lesions, erosions of the cartilage in weig htbeari ng joi nts , or other signs of arthropathy .
ADVER SE REA CTIONS In the Phase III registration trials, a total of 885 subjects were treated with ofloxacin otic solution. This included 229 subjects with otitis externa (with intact tympan ic membranes) and 656 subjects with acute otitis media with tympanosto my fubes or chro nic suppurative otitis media with perforated tympanic membranes. The reported treatment-related adverse events are listed below :
Subiects with Otitis Externa T he following treatment-related adverse events occurred in 1% or more of the subjects with intact tympanic membranes.
Other treatment-related adverse reactions reported in SUbjects with non-intact tympa nic membranes included: diarrhea (0.6%) , nausea (0.3%) , vomi ting (0.3%) , dry mouth (0.5%) , headache (0.3%), vertigo (0.5%), otorrhagia (0.6%) , tinnitus (0.3%) , fever (0.3%) . T he following treat ment-related adverse events were eac h reported in a single subjec t: application site reaction , otitis externa , urticaria, abdomi nal pain, dysaesthesia, hyperkinesia, halitosis, inflammation, pain, insomnia, coughing, pharyngitis, rhinitis, sinusitis, and tachycardia.
DOSAGE AND AD MINI STRATIO N Ot iti s Ext ern a: T he recommended dosage regimen for the treatment of otitis externa is: For pedia tric patients (from 1 to 12 years old) : Five drops (0.25 mL, 0.75 mg olloxaci n) instilled into the affected ea r twice daily for ten days. For patients 12 yea rs and older:Ten drops (0.5 mL, 1.5 mg ofloxacin) instilled into the affected ear twice daily for ten days. The solution should be warmed by ho lding the bottle in the hand for one or two minutes to avoid dizziness which may result from the instillation of a co ld solution. The patient shou ld lie with the affecte d ear upward, and then the drops should be instilled. This position should be maintained for five minutes to facilitate penetration at the drops into the ear ca nal. Repeat, if necessary, for the opposite ear.
Acute Otiti s Med ia in ped iatric p ati en ts w ith ty mp anostomy tu bes: Th e recommended dosage regimen for the treatment of acute otitis media in ped iatric patients (from one to 12 years old) with tympanostomy tubes is: Five drops (0.25 mL, 0.75 mg ofloxacin) instilled into the affec ted ear twice da ily for ten days. The solutio n should be warmed by holding the bottle in the hand for one or two minutes to avoid diz zn ess which may result from the instillation of a cold solution. The patient should lie wit h the affected ea r upward , and then the drops shou ld be insti lled. The tragus should the n be pumped 4 times by pushing inward to facilitate penetrat ion of the drops into the middle ea r. This positio n shou ld be maintained for five minutes. Repeat , if necessary, for the opposi te ear.
Chroni c Sup p urati ve Ot itis Med ia w ith p erfo rated t ympanic membran es: T he recommended dosage regimen for the treatmen t of chro nic suppura tive otitis media with perforated tympanic memb ranes in patients 12 years or olde r is : Ten drops (0.5 mL, 1.5 mg ofloxaci n) inst illed into the affected ear twice daily for fourtee n days . The solution sho uld be wa rmed by holding the bott le in the hand for one or two minutes to avoid dizzi ness which may resu lt from the instillation of a cold solution . cultures sho uld be obtained to guide fur ther treat me nt. If otorrhea persists afte r a full course of therapy, or if two or more episo des of oto rrhe a occ ur within six months, furthe r evaluation is recommended to exclude an unde rlying co nditio n such as cholesteatoma, foreign body, or a tumor.
The system ic adm inistration of quinolones, includi ng ofloxacin at doses much highe r than given or absorbed by the otic route, has led to lesions or erosio ns of the ca rtilage in weig ht-bea ring joints and other sig ns of arthropathy in imm ature animals of various species .
Young growing guinea pigs dosed in the middle ear with 0.3% ofloxac in otic so lution showed no syste mic effects, lesions or erosions of the cartilage in weight-bear ing jo ints, or other signs of arthropathy. No drug-related structural or functional changes of the coch lea and no lesions in the ossic les were noted in the guinea pig followi ng otic administrat ion of 0.3% ofloxaci n for one month.
No signs of local irritation were found when 0.3% ofloxacin was applied topically in the rabbit eye. Of loxacin was also shown to lack de rmal sens itizing potentia l in the guinea pig maximization study.
Information for Pati en t s: Avoid contaminating the applicato r tip with material from the fingers or other so urces . This precaution is necessary if the sterility of the drops is to be preserved. Systemic quinolones, includ ing ofloxacin , have bee n assoc iated with hypersensitivity reactions, even following a sing le dose . Discontinue use immediately and contact your physician at the first sign of a rash or allergic reaction.
Otitis Ext erna
Prior to adm inistratio n of FLOXIN" Otic in patients with otitis exte rna , the so lution sho uld be warm ed by holdin g the bott le in the hand for one or two minutes to avoid dizzi ness which may result from the instillation of a cold solution. The patient should lie with the affected ea r upward, and then the drops should be instilled. This position should be maintained for five minu tes to facilitate penetration of the drops into the ea r canal. Repeat, if necessary, for the oppos ite ear (see DOSAGE AND AD MINISTRATION).
Acute Otitis Med ia and Chronic Su ppurative Ot it is Medi a In pediatric patients (from 1 to 12 years old) with ac ufe otitis media with tympanos tomy tubes and in patients with chronic suppurative otitis media with perforated tymp anic membranes, prior to adm inistration, the solution should be wa rmed by holding the bottle in the hand for one or two minutes to avoid dizziness w hich may result from the instillation of a col d so lution. The patient sho uld lie with the affected ea r upwa rd, and then the drops shoul d be instilled. T he tragus sho uld then be pump ed 4 times by pushing inwar d to facilitate penetratio n of the drops into the middle ear. This position sho uld be maintained for five minutes. Repeat, if necessary, for the opposi te ea r (see DOSAG E AN D AD MIN ISTRATION).
Drug Int er act ions : Spec ific drug inte ractio n studies have not been cond ucted with FLOXIN" Otic.
Carcinogen esi s, Mut ag enes is , Imp airm en t of Fertility Long-term studies to determine the carcinogen ic pote ntial of ofloxac in have not been conducted. Olloxacin was not mutagen ic in the Am es test, the sister chromati d excha nge assay (Chinese hams ter and huma n ce ll lines) , the unscheduled DNA synthesis (UDS) assay using human fibroblasts , the dom inant lethal assay, or the mouse micro-nucleus assay. Of loxacin was positive in the rat hepatocyte UDS assay, and in the mouse lymphoma assay. In rats, ofloxaci n did not affect male or female reproductive performa nce at oral doses up to 360 mglkg/day. This wou ld be over 1000 times the maximum recommended clinical dose , based upon body surface area , assuming total abso rptio n of ofloxacin from the ear of a patient treated with FLOXIN" Otic twice per day. Pr egn ancy Terato gen ic effects: Pregn an cy Cat ego ry C. Ofloxaci n has bee n shown to have an embryocida l effect in rats at a dose of 8 10 mglkg/day and in rabbits at 160 mglkg/day. In Contextualism, moral conflicts invo lve hard choices that ca nnot be reduce d to cas uis try (Deonto logy) or to a simp le cos t-bene fit ana lys is (Co nseq uentialism); both prin ciples and co nsequences mu st be reckoned wi th. Co ntex tua lism prop oses that et hical so lutio ns ca nnot be ade quately regulated by statute. Rath er , those who make a mor al dec is ion, ex cept in exceptio na l circ umstances, ought to be those who will ac tua lly bear the bu rden of that decision . In thi s theory, life is of pe nultimate (ra ther tha n ulti mate) va lue, and it ca nnot be sacrificed fo r trivial reasons . Et hical theories give us a basis for devel oping our ow n ethica l positi on s on a myriad of di fficu lt issues that co nfront medi cin e tod ay. Physicians deal wit h these issues on a daily basis. T o a d ispr op ortion ate ex te nt, it is our ge ria tric pat ient s whose ca re necessit ates these difficult dec isions . Th e fo llowing areas of ethical co nce rn for physicians are meant as a guide line for dealing with so me of these iss ues .
Inform ed consent
As a prin cipl e of medi cal ethics, in formed co nse nt has a stro ng influe nce on the physician-patient relat io nship. In medicin e, informed co nse nt is "a n auto no mo us authoriza tio n by a patient or su bject." Its co mpone nts are co mpeten ce, disclosure, co m prehe nsio n, and vo luntary choice.I For the infi rm elde rly, thi s prin cipl e has a un iqu e significa nce . Aged pa tients are ofte n co m pro mised in terms of co mprehe nsion, co mpe te nce , and their ability to make ' vo luntary choices abo ut thei r ow n care. Complica ting the matter is the fac t tha t co mpre he ns ion is so me times difficult to ascertain .
Th e legal basis for consent places the res po nsib ility on the physic ian to inform the patient fully. Th e legal ca uses of action tha t result from absent or insu fficient informe d co nse nt are negl igen ce and battery. Th e pat ient' s co mpetence to make an aut onom ou s decision based on discu ssio ns wit h th e ph ysi ci an ap plies o nly to rece iving health care , In the clinical se tti ng, the res po ns ibi lity for determ in ing w he the r the pati ent is ab le to give informed co nse nt also resides wi th the physician.
Once the ph ysici an has es tab lis hed the pat ien t' s co mpetence, discl osure is made. During this stage of the co nse nt process, the physician ex p lai ns the risks, ben efits, procedure, and alt ern at ives regarding a par ticul ar mode of treatment. After discl osure, the pati en t' s co mprehe nsio n is assessed, w hich ca n be another pitfall in adv ising the elderly patient. Co mprehe nsio n does no t mean a profoun d degree of und er standing ; rather, it ca n mean only adeq uate unde rs ta ndi ng, co mparable with what wo uld be ex pected fro m any " reasonable patient" und er simila r circums ta nces . Fi na lly , the pat ient mus t be permitted to decid e free of ex te rna l co nstraints .
T he va lue of these precep ts is dep endent on subjective judgm ent s made by the phys ician. T he refore, when a 424 ph ysician ha s made a co nsc ientio us effo rt to inform the patient and to assess co mprehe nsio n, he or she ha s fulfille d the ethica l resp on sibil ity regarding these aspects of infor med consent.
Autonomy and surrogacy
Th e prin ciple of autonomy gra nts pati ents the right to make person al ch oi ces regarding their medic al care that they bel ieve are in their ow n best int erests. Implicit in thi s notion is the right to be informed of the nature of their d ise ase and the appropriate avenu es of treatmen t. Pati ent s then have the au thor ity to accept or rej ect the rec ommended therap y or to see k oth er opinions.
Wh en patients are deemed incapable of making suc h a decision, a surrogate ca n act on the ir beh al f. Issu es of aut on om y aris e more ofte n in geriatric pr acti ce than in ge neral pract ice, and thu s the need to es ta blis h surrogacy is greate r. For instan ce, an 86-year-o ld nur sing home resi de nt with ad van ce d he ad and neck canc er mi gh t be a poor candida te fo r heroic surgery, and suc h a patient mi ght find it difficult to make a rati on al decision ba sed on a co ns ideratio n of the di sease burden and the burden of treatment. Th e legal aspect of ethics provides guidelines th at ca n help the phy sician resol ve such a dil emma, so me times with assist ance fro m a sur rogate.
It must be emphasized that surrogacy sho uld be co nsidered a va lid optio n onl y aft er all att em pts to es tablish the patien t' s auto no my ha ve been ex hausted. Ide ally , a surroga te will have already been designated fo r the pati ent before the need arises. Wh en thi s is not the case, state law usually decides the issu e. Suitable ca ndida tes to serve as surrogates, ra nke d according to their re latio ns hip with the pat ien t, are guar dians, spo uses, adult childre n, parent s, siblings, adult gra ndc hi ldre n, and cl ose friend s.
Wh en a patient chooses a surrog ate, it is impo rtant to co nsider the surrogate's availability and pro xim ity , because co mplete care ca n require co nside rable tim e and effort. Th ese need s might be neglect ed if the patient and surrogate do not live in the same area. In additio n, the potential for abuse or evasion of the surrogate 's role is perhaps grea ter for elde rly patients. Thi s is particul arly true when there is d iscord in the famil y. Even wh en a va lid surrogate makes a careg iving decision , there are times when insti tutiona l or j udic ial revi ew and/or inter venti on becom e necessary. Su ch situatio ns can arise wh en family members do not agree on what is in the best interest of the patien t. Out side intervent ion ca n also be calle d for when a healthcare provider beli eves that the family's decision is clearl y not wha t the pati ent wo uld ha ve wa nted or when a healthcare provider believes that a surrogate 's deci sion cannot reaso nably be judged to be in the patient ' s best interest. The AMA reco mmends that such matters be brought before an institution al ethics committee before any of the parti es reso rts to the co urts to resol ve such disputes.' The terminally ill Caring for the terminally ill patient is always difficult , particul arly so when one co nsiders the ex plosiv e increase in medical tec hnology . Decision s made within the confines of medi cal ethics are more difficult because of deb ates over the definition s of irreve rsible pathology, irrevo cable death , and death itself. Scienti fic adva nces have blur red the previou sly distinct landma rks in the natura l progression of disea se. Legal and ethica l conse nsus on what co nstitutes biological death has changed dram atically. There is every indica tio n that the currently acce pted definitions of cli nical death will also dissol ve and give way to newer ideas in time. Providing an irrefutable frame of reference to help physicians decid e when a patient' s condi tio n has become term inal is therefore difficult. Th e princ iple of patient auto nomy requ ires that the physician respect the decision to forego life-s ustai ning trea tment by a patie nt who possesses deci sion-m akin g capacity. A co mpete nt adult patie nt may provide in advance a valid con sent to withhold or withdraw lifesuppor t sys te ms after illness has re ndered that patient incom petent to make such a decision .
Eve n whe n decisions do not co mpro mise ethica l dictates, physicians still face difficult cho ices . In essence , they may choose to continue a curre nt therapy, to institu te new or additional treatmen t, or to cease therapy or support. Each of these options must be consi de red in accordance with the pr inciples of informed conse nt, the wis hes of the patien t and fam ily, and established legal, moral, and ethical guide lines . Here the idea of "futility" weig hs heavily on the physician . A j udgment of futilit y is best achieve d within the co ntext of co nse nsus and coo pera tion between the physician and the pa tie nt or surrog ate. Ultimately, our primary aim is to limit the needl ess prolon gation of suffe ring.
In so me states and under so me circumstances , it is lawful to term inate artificial support to an individual who is in a persistent vege tative state witho ut invol ving the court sys tem, provided that such an action is agreed to by a close famil y member and approved by two qualified physicians. Still , cau tion must always be exercised , eve n when the ph ysician has the co nse nt of a surrogate, because state laws vary in this regard.
AMA guide lines specify that the ca reg iver's pr imary co nsideration sho uld be the best interest of the patient. Co ncerns abo ut burdens on family or soc iety sho uld not be allowe d to preju dice qu ality-of-life issues, altho ugh in truth they ofte n do.'
Suicide and euthanasia
Physician-assisted suicide has always been controversial, and the Kevorkian case has reki ndled the debate in the Un ited States. Cer tainly, it is und erstandable how patie nts 4 26 who are under extreme duress and who suffer from terminal , painful , or deb ilitating illn ess would pre fer death to life. But co nve ntional ethica l doctrine look s upon the practice with derision. The issue has go uged sharp lines of disput e that separate moral, legal , and medical pro tago nists. Physici an-assisted suicide is con sidered by many to be inco mpatible with the physician ' s ro le as a healer. However , that idea l is called into qu estion wheneve r a physician is no lon ger able to heal and is no longer capable of allev iating pain short of inducing a morp hine coma. Th en what do we do?
Many legisla tors be lieve that assisted suicide wo uld be difficul t, perh ap s imposs ible, to con trol. Others thin k it wo uld pose serious soc ieta l risks because it might eve ntually be extended to include inco mpe tent patient s and other vulnerable popul ations. We can argue that in the Netherla nds, assisted suicide is legal, and the laws that govern it are seldo m deviated from. But eve n though Kevo rkian was rece ntly convicted of second-degree murder, there is still no pro mise of an emergi ng consensus.
No r is there conse nsus on the diffe rence between heroic and atten dan t measures. To make an ethically bindin g decision , the physic ian attending the term inally ill must consider the burde ns of treatment, the wishes of the patient and family, the prescribed co de of ethics, and the res trai nts of legal statutes . The phy sician should seek advice on multid isc iplinary inter venti on s, incl udin g specia lty consultatio n, hospice care, pas tor al support, family co unse ling, and other mod alitie s. Pati ents near the end of their lives must co ntinue to receive emotional suppor t, comfort care, pain co ntrol, respect for their auto nomy, and maint en ance of meaningful co mmun ica tio n with caregivers.
Do-not-resuscitate orders
Th e phys ician is ethica lly bound to honor the desires of the patient regarding resuscitative intervention . Th is requires fully info rming the patient of the relevant co ncepts of ca rdio pulmonary res usci tation (CPR) as early as possible dur ing hospit alizati on. It is crucial that the patient ' s pre fere nces be pro perly and for mally document ed and be made accessible to all caregivers. Wh en it has been estab lished that the patient desires not to be resuscitated in the eve nt of a cardio pulmo nary arres t, the phy sician is required to docum ent this do-n ot-r esuscit ate (DNR) order in the medical record.
Eve n when there is no formal DNR order, physicians who are admi nis tering CPR often realize that continuing their res usc itative efforts will not res tore susta inable cardiopulmo nary ac tivity. In such instances, the physicia n can choose to cease CPR efforts. Such a decision mu st not conflic t with the wis hes of the pat ient or the decision of the surrogate. 
ENT-Ear, Nose
BAH
A® is a first-line treatment optio n fo r co nd uc tive hearin g loss due to bilat eral .fi.. a tre sia or ch ro nic suppe ra tive o titis med ia. Unti l now BAHA, along with ou r ret ention system for fac ial p ro sth eses, h as been produced an d market ed by Nob el Biocare.
WE HAVE NOW FORMED a new co mpany ca lled Entifi c Medical Syste ms. Nobe l Biocar e will remain as one of th e owne rs an d will continue to supply us with Branemark System" surgical co m po nen ts.
THE BIG DIFFERENCE is that we will now be ab le to increase o ur program of product and market development in close partnership with our custome rs. Our vision is th at o ur unique product syste m will improve th e quality of life for thousands of new pati ents all ove r the worl d .
THE FUTURE LOO K S EXCITI NG . We will so on be lau n ch ing bo th n ew an d improved p roducts. We are also looking at o ther app lica tions based o n osseo in tegratio n . Our visio n is clear. There are patien ts in n eed all over the world. In partnership with you, we will co ntinue to strive for the best treatmen t for all of these patien ts. O thers might arg ue that a significant nu mber of people in their 80s and 90s co ntinue to enjoy active, meaningful , and productive lives. Moreover, evidence is mou nting that the re is no significant age d iffe re nce in mortal ity or morbidity outco mes assoc iated wit h various interventio ns.>" So there mu st ce rta inly be so me co nsideratio n of individual circ ums ta nces .
Medical
Rati on ing of medical ca re in so me fo rm see ms inevitable, altho ugh most peop le are uncomfortable mak ing these difficult choices. In Br itain, for example, indi vid ual s olde r than 55 w ho requ ire di alysi s are no lon ger covered by the Nat iona l Health Se rv ice. It is hoped that co nsta nt vigila nce and co nsta nt ana lys is will res ult in an ethical sys te m of rat ion ing that is fair , both to socie ty as a who le and part icul arl y to the vulnerable ge ria tric populati on .
Epilo gue
Th e ethical guide lines suggested in this ar ticle are roo ted in j ud icia l decisio ns. For examp le, informe d co nse nt was addressed in cases such as Cant erbury v. Spen ce ( 1972), autonomy in cases suc h as Scho lendorff v. Nell ' York Hospital ( 1914) and Fosnti re v. Nicoleau (1990) , and te rmina l illn ess in cases such as In re Quin lan ( 1976) . Yet it is ethical doctrine rat her than ca se law that provides a philosophica l purch ase up on which all ac tio ns res t. T he onus is on the ph ysici an to rem ain bound within this struct ure , to re ma in cr itica l of his or her moral posit ion , and above all to co ntin ue to be refl ecti ve.
LOCATOR, INC.
MedNet
Rat io nin g of medi cal care Can we do everyth ing for everybody? The clash be twee n rising expectations and cost limitations has forced us to ret hink our abi lity to pro vide essentially unlim ited development of and access to hcalthcare. Q uestions now arise as to whether it is acceptab le to limit healthcare because of econo mic co nsideration s. Cen tra l to these questio ns is the co nce pt of rationing medi cal care.
Ca lla han has suggested that "our co m mon social ob ligation to the elde rly is only to help the m live out a natu ral lifesp an ; that is, the govern me nt is ob lige d to prov ide lifeex tendi ng healthcare only to the age that is necessary to ac hieve that goal.":' Ca lla ha n ha s det er min ed that age 65 is the age at w hich life ' s goals can be sa id to be achi eved ; beyond that age, cos t-be ne fit advantages are lost. He arg ues that pas t age 65, rel ief of suf feri ng is all that is clinica lly requ ired ; it is not prudent to kee p peopl e ph ysiologically alive at extraordin ary cost. Ca lla han poi nts out that of the one-th ird of our co untry' s healthcare ex pe nd itur es spent on peop le olde r than 65 , nea rly hal f is spent during the last year of life. T he result is an immen se expe nse for littl e if any benefit. 
